Attovia Therapeutics, Inc. (ATTO) company profile
Close on Nov 17, 2026Market cap $678.38MP/E –Yield –
About Attovia Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Attovia Therapeutics, Inc. is listed on Nasdaq under the ticker ATTO, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Attovia Therapeutics, Inc.
- Headquarters
- San Carlos, CA
- Address
- 1091 Industrial Road 94070
- Phone
- (510) 399-5001
- Website
- attovia.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- ATTO
- Exchange
- Nasdaq
- IPO date
- Aug 5, 2026
- Shares outstanding
- 46M, Aug 31, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2058707
- CUSIP
- 04987L102
- ISIN
- US04987L1026
- FIGI
- BBG01H3TV5J8
- Share class FIGI
- BBG01H3TV5L5
- EIN
- 92-1510574
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Tao Fu | President and CEO, Director | 333,268 |
| Attovia Therapeutics, Inc. | President and CEO, Director | 449,371 |
| Steven Chan | Chief Financial Officer | – |
| Petter Veiby | Chief Scientific Officer | 104,951 |
| Hubert Chen | Chief Medical Officer | 2,960 |
| Zaneta Odrowaz | Chief Business Officer | 103,269 |
| Colin Walsh | Director | 2,520,632 |
| Angie You | Director | 52,852 |
| Mitchell Gold | Director | – |
| John W. Smither | Director | – |
| Aaron Royston | Director | – |
| James N. Topper | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 5, 2026
- Offer price
- $17.00
- Securities offered
- 17,000,000
- Gross proceeds
- $289.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Feb 1, 2027
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 5, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 29, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?